InvestorsHub Logo
Followers 145
Posts 27599
Boards Moderated 3
Alias Born 02/07/2004

Re: tykundegex post# 2552

Tuesday, 12/15/2020 12:50:14 PM

Tuesday, December 15, 2020 12:50:14 PM

Post# of 3892
RedHill Biopharma's opaganib shows encouraging action in animal study

Dec. 15, 2020 10:51 AM ETRedHill Biopharma Ltd. (RDHL)By: Vandana Singh, SA News Editor

RedHill Biopharma (RDHL +3.9%) has announced promising preliminary results from a preclinical study within which opaganib, an orally administered sphingosine kinase 2 selective inhibitor, demonstrated a reduction of thrombosis (blood clotting) in an acute respiratory distress syndrome (ARDS) animal models.

Opaganib has also been shown to inhibit SARS-CoV-2 viral replication as well as pro-inflammatory markers in relevant preclinical models.

Top-line data from an ongoing global Phase 2/3 study of opaganib in patients with severe COVID-19, is expected in Q1/2021 with potential global emergency use applications to follow.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RDHL News